Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. Salivary Gland Cancer - Pipeline Review, H2 2014

    Commentary

    Wed, 21 Jan 2015

    Cancer - Companies Involved in Therapeutics Development AstraZeneca PLC Bayer AG Incuron, LLC Novartis AG Otsuka Holdings ..... Institutes, H2 2014 Salivary Gland Cancer - Pipeline by AstraZeneca PLC , H2 2014 Salivary Gland Cancer - Pipeline by Bayer

  2. UPDATE 2- AstraZeneca heart drug boosted by major clinical trial success

    Headlines

    Wed, 14 Jan 2015

    * AstraZeneca shares up 1.5 percent (Adds executive interview, consensus sales forecast, more reaction)

  3. BRIEF- AstraZeneca says heart drug study meets primary endpoint

    Headlines

    Wed, 14 Jan 2015

    * PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint

  4. Leader in Genomic Sequencing Illuminates the Way

    Headlines

    Wed, 14 Jan 2015

    machines like NextSeq following shortly. Illumina has also announced gene panel test partnerships with Johnson & Johnson, AstraZeneca , Sanofi, and Amgen (for Vectibix). Management Faces a Tall Order in Sustaining Illumina's Leadership We rate Illumina’s stewardship rating

  5. AstraZeneca loses German court appeal over Seroquel XR drug patent

    Headlines

    Tue, 13 Jan 2015

    KARLSRUHE, Germany, Jan 13 (Reuters) - Britain's AstraZeneca Plc on Tuesday lost an appeal in Germany's Federal Court against generic drugmakers selling cheap copies of its anti-psychotic drug Seroquel XR.

  6. AstraZeneca in cancer viruses deal with Omnis Pharmaceuticals

    Headlines

    Mon, 12 Jan 2015

    LONDON, Jan 12 (Reuters) - AstraZeneca said on Monday its MedImmune biotech unit had struck a deal with unlisted U.S. company Omnis Pharmaceuticals on the development of cancer-fighting oncolytic viruses.

  7. BRIEF- Astrazeneca's MedImmune signs licensing deal with Omnis Pharmaceuticals

    Headlines

    Mon, 12 Jan 2015

    * MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology

  8. Shake-up at AstraZeneca as two immuno-oncology leaders leave

    Headlines

    Mon, 5 Jan 2015

    * Immune-boosting cancer drugs critical to company's future

  9. Isis’ Deal with J&J Underlines Broad Potential of its Antisense Technology; Increasing FVE

    Commentary

    Mon, 5 Jan 2015

    add to its already long list of pipeline opportunities and strong commercialization partners (Sanofi, GSK, Roche, AstraZeneca , and Biogen). We are maintaining our no moat, positive trend rating as most of its pipeline is still unproven clinically

  10. Health Care: A Strong Run, but Some Stocks Still Look Undervalued

    Headlines

    Wed, 31 Dec 2014

    ABBV and Shire PLC SHPG. Further, the new environment makes it much less likely that Pfizer PFE will return to bid for AstraZeneca AZN following the failed attempt earlier in the year. However, the white knight acquisition of Allergan AGN by Actavis

« Prev12345Next »
Content Partners